Detalhe da pesquisa
1.
Recombinant human thrombopoietin (rhTPO) of different dosing regimens for refractory/relapsed primary immune thrombocytopenia: a multicenter, randomized controlled trial and pharmacokinetics study.
Platelets
; 34(1): 2157806, 2023 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-36597010